目的 探讨乳腺浸润性导管癌中G蛋白偶联受体30(GPR30)、HRG1和HER2及其激活状态磷酸化HER2(pHER2)的表达与淋巴结转移的关系。方法 采用免疫组织化学方法检测72例乳腺浸润性导管癌组织样本中GPR30、HRG1、HER2和pHER2的表达。结果 GPR30与HRG1表达呈中度相关性(r=0.597,P=0.000);pHER2与GPR30或HRG1的表达呈强相关性(r=0.742,P=0.000;r=0.615,P=0.000);GPR30和pHER2表达在淋巴结转移组明显高于淋巴结未转移组,差异有统计学意义(P〈0.05)。结论 GPR30与HRG1-HER2信号途径存在相互联系,可能共同促进乳腺癌淋巴结转移,联合抑制这两条途径有望成为乳腺癌治疗的新策略。
Objective To explore the expression of GPR30, HRG1 and HER2 including the activation status of HER2 (phosphorylated HER2) in invasive ductal breast cancers and their relationship with lymphatic metastasis. Methods The expres- sion of GPR30, HRG1, HER2 and pliER2 in 72 cases of specimens of invasive ductal breast cancers were examined by immunohis- tochemistry method. Results A moderate correlation between GPR30 and HRG1 was disclosed (r=0. 597,P=0. 000). There was strong correlation between pliER2 and GPR30 or HRG1 ( r = 0. 742, P = 0. 000 ; r = 0.615, P = 0. 000). The expression of GPR30 and pliER2 in the lymphatic metastasis group was remarkably higher than in the group without lymphatic metastasis(P~0.05). Conclusion The interaction between GPR30 and HRG1 HER2 signal transduction pathways might be involved in the lymphatic metastasis in breast cancer. Blocking both of GPR30 and HRG1 signaling pathway could be a promising new strategy for breast cancer treatments.